• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Bias-force guided simulations combined with experimental validations towards GPR17 modulators identification
Biomed Pharmacother. 2023 Jan 28;160:114320. doi: 10.1016/j.biopha.2023.114320. Online ahead of print.ABSTRACTGlioblastoma Multiforme (GBM) is known to be by far the most aggressive brain tumor to affect adults. The median survival rate of GBM patient's is < 15 months, while the GBM cells aggressively develop resistance to chemo- and radiotherapy with their self-renewal capacity which suggests the pressing need to develop novel preventative measures. We have recently proved that GPR17 -an orphan G protein-coupled receptor- is highly expressed on the GBM cell surface and it has a vital role to play in the disease progres...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 30, 2023 Category: Drugs & Pharmacology Authors: Sana Kari Akshaya Murugesan Ramesh Thiyagarajan Srivatsan Kidambi Jamoliddin Razzokov Chandrabose Selvaraj Meenakshisundaram Kandhavelu Parthiban Marimuthu Source Type: research

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
Biomed Pharmacother. 2021 Dec 11;146:112532. doi: 10.1016/j.biopha.2021.112532. Online ahead of print.ABSTRACTBrain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, gliobla...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 15, 2021 Category: Drugs & Pharmacology Authors: Mahshid Deldar Abad Paskeh Atefeh Mehrabi Mohammad Hossein Gholami Amirhossein Zabolian Ehsan Ranjbar Hossein Saleki Adnan Ranjbar Mehrdad Hashemi Yavuz Nuri Ertas Kiavash Hushmandi Sepideh Mirzaei Milad Ashrafizadeh Ali Zarrabi Saeed Samarghandian Source Type: research

The enzyme L-isoaspartyl (D-aspartyl) methyltransferase promotes migration and invasion in human U-87 MG and U-251 MG glioblastoma cell lines
Biomed Pharmacother. 2021 May 31;140:111766. doi: 10.1016/j.biopha.2021.111766. Online ahead of print.ABSTRACTThe protein L-isoaspartyl (D-aspartyl) methyltransferase (PIMT) recognizes abnormal L-isoaspartyl and D-aspartyl residues in proteins. Among examined tissues, PIMT shows the highest level in the brain. The U-87 MG cell line is a commonly used cellular model to study the most frequent brain tumor, glioblastoma. Previously, we reported that PIMT amount increased when U-87 MG cells were detached from the extracellular matrix. Recently, we also showed that PIMT possessed pro-angiogenic properties. Together, these PIMT ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 3, 2021 Category: Drugs & Pharmacology Authors: Fatima Belkourchia Richard R Desrosiers Source Type: research

Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells.
CONCLUSIONS: We demonstrated that HOXA11-AS acted as an oncogenic lncRNA that promoted cell growth and metastasis of glioma through regulating miR-214-3p/EZH2 axis. These results suggested HOXA11-AS may serve as an efficient marker and a potential therapeutic target for glioma. PMID: 28946213 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 20, 2017 Category: Drugs & Pharmacology Authors: Xu C, He T, Li Z, Liu H, Ding B Tags: Biomed Pharmacother Source Type: research